BWA
UTHR icon

Basecamp Wealth Advisors’s United Therapeutics UTHR Stock Holding History

Basecamp Wealth Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.2K Sell
41
-3
-7% -$1.69K ﹤0.01% 773
2026
Q1 		$26.1K Buy
44
+16
+57% +$7.97K 0.01% 737
2025
Q4 		$13.6K Buy
+28
New +$13K ﹤0.01% 886

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Basecamp Wealth Advisors's UTHR Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its United Therapeutics (UTHR) stake by 6.8% in Q2 2026, selling an estimated $1.69K and leaving 41 shares worth $22.2K. The position accounts for ﹤0.01% of the portfolio, ranked #773.

Basecamp Wealth Advisors first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $26.1K in Q1 2026. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Basecamp Wealth Advisors held 41 shares of United Therapeutics worth $22.2K as of Q2 2026.
  • Basecamp Wealth Advisors sold 3 United Therapeutics shares in Q2 2026, an estimated $1.69K.
  • United Therapeutics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #773 holding.
  • Basecamp Wealth Advisors first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's United Therapeutics position peaked at $26.1K in Q1 2026.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.